-
公开(公告)号：US10562900B2
公开(公告)日：2020-02-18
申请号：US15504854
申请日：2015-08-19
Applicant: Shanghai Haihe Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Inventor： Meiyu Geng , Lei Liu , Lei Jiang , Min Huang , Chuantao Zha , Jing Ai , Lei Wang , Jianhua Cao , Jian Ding
IPC: C07D487/04 , C07D231/56 , C07D519/00 , C07D401/12 , C07D471/04 , C07D403/12 , C07D498/04 , C07D401/14 , C07D405/14 , C07D417/12 , A61K31/416 , A61K31/496
Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
-
公开(公告)号：US10710996B2
公开(公告)日：2020-07-14
申请号：US15575903
申请日：2016-05-23
Inventor： Yaqiu Long , Meiyu Geng , Zhongliang Xu , Jing Ai
IPC: C07D471/04 , A61K31/501 , A61K31/4985 , A61K31/4375 , A61K31/496 , A61K31/4545 , A61K31/444 , A61K31/5377 , A61P35/00
Abstract: The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.
-
公开(公告)号：US20210261539A1
公开(公告)日：2021-08-26
申请号：US16967664
申请日：2019-02-01
Applicant: Shanghai Haihe Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Inventor： Lin Xia , Meiyu Geng , Yan Ye , Jian Ding , Qiong Zhang , Aijun Shen , Ying Huang , Hongchun Liu , Haoran Yang , Jing Ai , Minmin Zhang
IPC: C07D471/04 , C07D519/00 , C07D403/04 , C07D498/04 , C07D401/14 , C07D487/04 , C07D413/14
Abstract: The invention relates to the field of pharmaceutical chemistry. Specifically, the present invention relates to a series of BET (bromodomain and extra-terminal domain) inhibitors having a novel structure, particularly inhibitors targeting BRD4 (Bromodomain-containing protein 4), and a preparation method and use therefor. The structure thereof is shown in the following general formula (I). Said compounds or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or crystal form thereof, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition thereof can be used for the treatment and/or prevention of related diseases mediated by bromodomain proteins.
-
4.发明申请SULFATED POLYGULONIC ACID POLYSACCHARIDE OR PHARMACEUTICAL SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF 审中-公开硫化聚氨酯多糖或其药物盐，其制备方法及其用途公开(公告)号：US20160367591A1
公开(公告)日：2016-12-22
申请号：US14901297
申请日：2014-07-02
IPC: A61K31/737 , C08B37/00
CPC classification number: A61K31/737 , C08B37/0084 , C08L5/00
Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and actin-aggregation inhibitors.
Abstract translation: 公开了多糖酸硫酸盐或其药学上可接受的盐，其制备方法及其在制备肿瘤生长和/或转移抑制剂中的用途。 本发明的多糖酸硫酸盐或其药学上可接受的盐可用于制备肿瘤生长抑制剂，肿瘤转移抑制剂，血管生成抑制剂，乙酰肝素酶抑制剂，C-Met酶抑制剂，微管聚合抑制剂，肌动蛋白 聚合因子活性抑制剂和肌动蛋白聚集抑制剂。
-
5.发明授权公开(公告)号：US11834432B2
公开(公告)日：2023-12-05
申请号：US15998927
申请日：2017-02-17
Inventor： Ao Zhang , Meiyu Geng , Li Xing , Jing Ai , Zilan Song , Xia Peng , Wangting Gu , Jian Ding
IPC: C07D213/75 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61P35/00 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4433 , A61K31/4409 , A61K31/496 , A61K31/506 , A61K31/5355 , A61K31/5377 , A61K31/4545 , A61K31/44
CPC classification number: C07D401/12 , A61P35/00 , C07D213/75 , C07D403/12 , C07D405/12 , C07D413/14 , C07D417/14
Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US10988456B2
公开(公告)日：2021-04-27
申请号：US16487385
申请日：2018-02-12
Inventor： Youhong Hu , Meiyu Geng , Wenming Ren , Jian Ding , Xiaocong Guan , Jing Ai , Lang Wang , Xia Peng , Yang Liu , Yang Dai , Limin Zeng
IPC: C07D401/12 , C07D405/14 , C07D403/12 , A61P35/00 , B01J31/24 , B01J27/122 , B01J31/30
Abstract: An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.
-
公开(公告)号：US10683278B2
公开(公告)日：2020-06-16
申请号：US15752896
申请日：2016-08-18
Inventor： Ke Ding , Meiyu Geng , Li Tan , Jian Ding , Zhang Zhang , Jing Ai , Xiaomei Ren , Donglin Gao , Zhengchao Tu , Xiaoyun Lu , Dongmei Zhang
IPC: A61K31/4709 , C07D215/233 , C07D401/12 , C07D471/04 , C07D471/06 , C07D487/04 , C07D491/048 , C07D498/06 , C07D513/04 , C07D519/00
Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
-
公开(公告)号：US10058566B2
公开(公告)日：2018-08-28
申请号：US14901297
申请日：2014-07-02
IPC: A61K31/737 , C08B37/00 , C08L5/00
CPC classification number: A61K31/737 , C08B37/0084 , C08L5/00
Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerizing factor activity inhibitors and actin-aggregation inhibitors.
-
公开(公告)号：US09567342B2
公开(公告)日：2017-02-14
申请号：US14926729
申请日：2015-10-29
Applicant: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Inventor： Weibo Wang , Meiyu Geng , Jian Ding , Xingdong Zhao , Jing Ai , Qiang Tian , Xia Peng , Weipeng Zhang , Hongbin Liu , Haohan Tan , Ling Chen
IPC: A61K31/506 , C07D487/04 , C07D405/12 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/14
CPC classification number: C07D487/04 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/12 , C07D405/14 , A61K2300/00
Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
Abstract translation: 本文公开了蛋白激酶抑制剂，更具体地是新颖的嘧啶衍生物及其药物组合物及其使用方法。
-
公开(公告)号：US09206166B2
公开(公告)日：2015-12-08
申请号：US14071953
申请日：2013-11-05
Applicant: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. , SHANGHAI iNSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Inventor： Weibo Wang , Meiyu Geng , Jian Ding , Xingdong Zhao , Jing Ai , Qiang Tian , Xia Peng , Weipeng Zhang , Hongbin Liu , Haohan Tan , Ling Chen
IPC: A61K31/506 , C07D405/12 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/14 , C07D487/04
CPC classification number: C07D487/04 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/12 , C07D405/14 , A61K2300/00
Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
Abstract translation: 本文公开了蛋白激酶抑制剂，更具体地是新颖的嘧啶衍生物及其药物组合物及其使用方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.02 seconds)
